WO2003038095A3 - Peptide isole du facteur de croissance hepatocytaire et ses variants, procede de preparation et utilisation en therapeutique en tant qu'agents antiangiogeniques - Google Patents

Peptide isole du facteur de croissance hepatocytaire et ses variants, procede de preparation et utilisation en therapeutique en tant qu'agents antiangiogeniques Download PDF

Info

Publication number
WO2003038095A3
WO2003038095A3 PCT/FR2002/003739 FR0203739W WO03038095A3 WO 2003038095 A3 WO2003038095 A3 WO 2003038095A3 FR 0203739 W FR0203739 W FR 0203739W WO 03038095 A3 WO03038095 A3 WO 03038095A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptide
preparation
therapeutic use
variants
growth factor
Prior art date
Application number
PCT/FR2002/003739
Other languages
English (en)
Other versions
WO2003038095A2 (fr
Inventor
Tatiana Merkoulova-Rainon
Original Assignee
Inst Vaisseaux Et Du Sang
Tatiana Merkoulova-Rainon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Vaisseaux Et Du Sang, Tatiana Merkoulova-Rainon filed Critical Inst Vaisseaux Et Du Sang
Priority to EP02795357A priority Critical patent/EP1442121A2/fr
Priority to JP2003540360A priority patent/JP2005508637A/ja
Priority to CA002465714A priority patent/CA2465714A1/fr
Priority to AU2002360156A priority patent/AU2002360156A1/en
Publication of WO2003038095A2 publication Critical patent/WO2003038095A2/fr
Publication of WO2003038095A3 publication Critical patent/WO2003038095A3/fr
Priority to US10/835,986 priority patent/US20050107296A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne une substance peptidique choisie parmi l'ensemble constitué par: (i) le peptide N issu de la chaîne α de HGF et ayant la séquence aminoacide représentée par SEQ ID No.: 2, et (ii) ses variants peptidiques dérivant de la séquence dudit peptide N par suppression, substitution ou addition d'un ou plusieurs aminoacides, ledit peptide N et ses variants ayant une activité antiangiogénique selon un mécanisme différent de la fixation compétitive avec HGF sur le récepteur HGF-R. Elle concerne également l'utilisation thérapeutique et le procédé de préparation de ladite substance peptidique, ainsi que (i) le fragment de DNA qui l'exprime, le plasmide contenant ledit DNA et la bactérie contenant ledit plasmide.
PCT/FR2002/003739 2001-10-31 2002-10-30 Peptide isole du facteur de croissance hepatocytaire et ses variants, procede de preparation et utilisation en therapeutique en tant qu'agents antiangiogeniques WO2003038095A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP02795357A EP1442121A2 (fr) 2001-10-31 2002-10-30 Peptide isole du facteur de croissance hepatocytaire et ses variants, procede de preparation et utilisation en therapeutique en tant qu'agents antiangiogeniques
JP2003540360A JP2005508637A (ja) 2001-10-31 2002-10-30 単離された肝細胞増殖因子ペプチドおよびその変異体、調製方法、ならびに抗血管新生薬としての、治療上の使用
CA002465714A CA2465714A1 (fr) 2001-10-31 2002-10-30 Peptide isole du facteur de croissance hepatocytaire et ses variants, procede de preparation et utilisation en therapeutique en tant qu'agents antiangiogeniques
AU2002360156A AU2002360156A1 (en) 2001-10-31 2002-10-30 Isolated peptide of the hepatocyte growth factor and its variants, preparation method and therapeutic use as anti-angiogenic agents
US10/835,986 US20050107296A1 (en) 2001-10-31 2004-04-29 Isolated peptide of the hepatocyte growth factor and its variants, preparation method and therapeutic use as anti-angiogenic agents

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR01/14146 2001-10-31
FR0114146A FR2831540B1 (fr) 2001-10-31 2001-10-31 Peptide isole du facteur de croissance hepatocytaire et ses variants, procede de preparation et utilisation en therapeutique en tant qu'agents antiangiogeniques

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/835,986 Continuation US20050107296A1 (en) 2001-10-31 2004-04-29 Isolated peptide of the hepatocyte growth factor and its variants, preparation method and therapeutic use as anti-angiogenic agents

Publications (2)

Publication Number Publication Date
WO2003038095A2 WO2003038095A2 (fr) 2003-05-08
WO2003038095A3 true WO2003038095A3 (fr) 2003-12-24

Family

ID=8868969

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2002/003739 WO2003038095A2 (fr) 2001-10-31 2002-10-30 Peptide isole du facteur de croissance hepatocytaire et ses variants, procede de preparation et utilisation en therapeutique en tant qu'agents antiangiogeniques

Country Status (6)

Country Link
EP (1) EP1442121A2 (fr)
JP (1) JP2005508637A (fr)
AU (1) AU2002360156A1 (fr)
CA (1) CA2465714A1 (fr)
FR (1) FR2831540B1 (fr)
WO (1) WO2003038095A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090169473A1 (en) * 2005-10-24 2009-07-02 Fujifilm Ri Pharma Co., Ltd. Diagnostic agent and therapeutic agent for disease associated with hepatocyte growth factor receptor
US9611297B1 (en) 2016-08-26 2017-04-04 Thrasos Therapeutics Inc. Compositions and methods for the treatment of cast nephropathy and related conditions

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040914A1 (fr) * 1995-06-07 1996-12-19 Chan Andrew M L Variants tronques du facteur de croissance des hepatocytes
EP1074264A1 (fr) * 1998-04-28 2001-02-07 NAKAMURA, Toshikazu Inhibiteurs de neovascularisation
WO2001044294A2 (fr) * 1999-12-15 2001-06-21 Entremed, Inc. Compositions et procedes d'inhibition de la proliferation de cellules endotheliales

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040914A1 (fr) * 1995-06-07 1996-12-19 Chan Andrew M L Variants tronques du facteur de croissance des hepatocytes
EP1074264A1 (fr) * 1998-04-28 2001-02-07 NAKAMURA, Toshikazu Inhibiteurs de neovascularisation
WO2001044294A2 (fr) * 1999-12-15 2001-06-21 Entremed, Inc. Compositions et procedes d'inhibition de la proliferation de cellules endotheliales

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
AOYAMA HIDEYUKI ET AL: "Isolation and conformational analysis of fragment peptide corresponding to the heparin-binding site of hepatocyte growth factor.", BIOCHEMISTRY, vol. 36, no. 33, 1997, pages 10286 - 10291, XP002207633, ISSN: 0006-2960 *
BELLE VAN E ET AL: "POTENTIATED ANGIOGENIC EFFECT OF SCATTER FACTOR/HEPATOCYTE GROWTH FACTOR VIA INDUCTION OF VASCULAR ENDOTHELIAL GROWTH FACTOR", CIRCULATION, AMERICAN HEART ASSOCIATION, DALLAS, TX, US, vol. 97, no. 4, May 1998 (1998-05-01), pages 381 - 390, XP002925550, ISSN: 0009-7322 *
BUSSOLINO F ET AL: "HEPATOCYTE GROWTH FACTOR IS A POTENT ANGIOGENIC FACTOR WHICH STIMULATES ENDOTHELIAL CELL MOTILITY AND GROWTH", JOURNAL OF CELL BIOLOGY, ROCKEFELLER UNIVERSITY PRESS, NEW YORK, US, US, vol. 119, no. 3, 1 November 1992 (1992-11-01), pages 629 - 641, XP000615596, ISSN: 0021-9525 *
DATE K ET AL: "HGF/NK4 IS A SPECIFIC ANTAGONIST FOR PLEIOTROPHIC ACTIONS OF HEPATOCYTE GROWTH FACTOR", FEBS LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 420, no. 1, 1997, pages 1 - 6, XP002920323, ISSN: 0014-5793 *
KUBA K ET AL: "HGF/NK4, A FOUR-KRINGLE ANTAGONIST OF HEPATOCYTE GROWTH FACTOR, IS AN ANGIOGENESIS INHIBITOR THAT SUPPRESSES TUMOR GROWTH AND METASTASIS IN MICE", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 60, no. 23, 1 December 2000 (2000-12-01), pages 6737 - 6743, XP001008887, ISSN: 0008-5472 *
MATSUMOTO ET AL: "Deletion of kringle domains or the N-terminal hairpin structure in Hepatocyte growth factor results in marked decreases in related biological activities", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 181, no. 2, 16 December 1991 (1991-12-16), pages 691 - 699, XP002017639, ISSN: 0006-291X *
S.J. STAHL ET AL: "Functional and biophysical characterization of recombinant human hepatocyte growth factor isoforms produced in Escherichia coli", BIOCHEMICAL JOURNAL., vol. 326, 1997, THE BIOCHEMICAL SOCIETY, LONDON., GB, pages 763 - 772, XP002207634, ISSN: 0264-6021 *
SAKATA H ET AL: "Heparin binding and oligomerization of Hepatocyte Growth Factor/Scatter Factor isoforms", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 14, no. 272, 4 April 1997 (1997-04-04), pages 9457 - 9463, XP002074885, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
JP2005508637A (ja) 2005-04-07
WO2003038095A2 (fr) 2003-05-08
FR2831540B1 (fr) 2004-07-09
FR2831540A1 (fr) 2003-05-02
EP1442121A2 (fr) 2004-08-04
AU2002360156A1 (en) 2003-05-12
CA2465714A1 (fr) 2003-05-08

Similar Documents

Publication Publication Date Title
WO2004043382A3 (fr) Variants ameliores de l'erythropoietine et methodes d'utilisation
WO2003012105A3 (fr) Isoforme de facteur de croissance
WO2003048202A3 (fr) Gène activant le facteur nucléaire kappa b
WO2002061076A1 (fr) Proteine associee a l'adiponectine
WO2002072616A3 (fr) Complexes de transfection
WO2003048205A3 (fr) Proteines a activite inhibitrice de l'il-6
AU8009601A (en) Polypeptides controlling phosphoric acid metabolism, calcium metabolism, calcification and vitamin d metabolism and dnas encoding the same
WO2002101052A3 (fr) Salutaridinol 7-o-acetyltransferase et derives de celle-ci
WO2001096527A3 (fr) Peptides à activité physiologique
EP1501936A4 (fr) Famille proteique de cytokine
BR9815285A (pt) Vetores alfavìrus para vacina de paramixovìrus
WO2003038095A3 (fr) Peptide isole du facteur de croissance hepatocytaire et ses variants, procede de preparation et utilisation en therapeutique en tant qu'agents antiangiogeniques
CA2327353A1 (fr) Proteines de structure du virus de la maladie affectant le pancreas des poissons et utilisations de ces dernieres
EP0816504A3 (fr) Facteur d'activation des plaquettes acétylhydrolase, et gène codant celui-ci
DK1425295T3 (da) Modificerede peptider og deres anvendelse til behandling af autoimmune sygdomme
DE60036676D1 (de) G-protein-gekoppelter rezeptor-ähnliche proteine
EP1467207A4 (fr) Methode de criblage
WO2007073845A3 (fr) Nouveau polypeptide presentant une activite d'esterase, esterase recombinee et leur utilisation
WO2002083727A3 (fr) Sequences d'acides nucleiques relatives a des hyperplasies et tumeurs de la glande thyroide
WO2002079471A3 (fr) Proteine d’ancrage des cholinesterases, acides nucleiques correspondants et leur application a la preparation de medicaments
WO2000052147A3 (fr) Prolyl peptidases et methodes d'utilisation
WO2003022300A1 (fr) Remedes prophylactiques et curatifs contre les maladies des os et des articulations
EP1096008A3 (fr) Récepteur humain couplé à une protéine G, PFI-014
EP1568775A4 (fr) Gene associe au cancer
EP0897984A3 (fr) Gène de deshydrogenase de sorbitol

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002795357

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2003540360

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 10835986

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2465714

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 2002795357

Country of ref document: EP